Population-based survival-cure analysis of ER-negative breast cancer
- 128 Downloads
This study investigated the trends over time in age and stage specific population-based survival of estrogen receptor negative (ER−) breast cancer patients by examining the fraction of cured patients and the median survival time for uncured patients. Cause-specific survival data from the Surveillance, Epidemiology, and End Results program for cases diagnosed during 1992–1998 were used in mixed survival cure models to evaluate the cure fraction and the extension in survival for uncured patients. Survival trends were compared with adjuvant chemotherapy data available from an overlapping patterns-of-care study. For stage II N+ disease, the largest increase in cure fraction was 44–60% (P = 0.0257) for women aged ≥70 in contrast to a 7–8% point increase for women aged <50 or 50–69 (P = 0.056 and 0.038, respectively). For women with stage III disease, the increases in the cure fraction were not statistically significant, although women aged 50–69 had a 10% point increase (P = 0.103). Increases in cure fraction correspond with increases in the use of adjuvant chemotherapy, particularly for the oldest age group. In this article, for the first time, we estimate the cure fraction for ER− patients. We notice that at age ≥70, the accelerated increase in cure fraction from 1992 to 1998 for women with stage II N+ compared with stage III suggests a selective benefit for chemotherapy in the lower stage group.
KeywordsSurvival Cure fraction Breast cancer ER− Chemotherapy
The authors wish to thank the editors, and the referees for comments and suggestions. Work (JJD) was supported in part by a research grant from the Susan G. Komen for the Cure Foundation. The clinical trials data for Fig. 1 generation was obtained under Public Health Service grants NCI-U10-CA-69651 and NCI-U10-CA-12027 from the U.S. National Cancer Institute.
- 3.Vogel VG, Costantino JP, Wickerham DL, National Surgical Adjuvant Breast, Bowel Project (NSABP) et al (2006) Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP? Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2727–2742CrossRefPubMedGoogle Scholar
- 10.Klein JP, Moeschberger ML (1997) Survival analysis: techniques for censored and truncated data, 2nd edn. Springer, New YorkGoogle Scholar
- 11.Mariotto AB, Feuer EJ, Harlan LC, Abrams J (2006) Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975–1999. J Natl Cancer Inst Mongr 36:7–15Google Scholar
- 16.Petrakis IE and Paraskakis S (2009) Breast cancer in elderly. Arch Gerontol Geriatr. doi: 10.1016/j.archger.2009.03.007